CN117562155A - 一种具有保肝护肝功效的保健茶 - Google Patents
一种具有保肝护肝功效的保健茶 Download PDFInfo
- Publication number
- CN117562155A CN117562155A CN202311495544.5A CN202311495544A CN117562155A CN 117562155 A CN117562155 A CN 117562155A CN 202311495544 A CN202311495544 A CN 202311495544A CN 117562155 A CN117562155 A CN 117562155A
- Authority
- CN
- China
- Prior art keywords
- parts
- liver
- flower
- health
- honey
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 51
- 230000036541 health Effects 0.000 title claims abstract description 23
- 230000002633 protecting effect Effects 0.000 title abstract description 15
- 241001122767 Theaceae Species 0.000 title description 29
- 241000244938 Penthorum chinense Species 0.000 claims abstract description 26
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 24
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 24
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 24
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 24
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 24
- 150000004676 glycans Chemical class 0.000 claims abstract description 24
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 24
- 239000005017 polysaccharide Substances 0.000 claims abstract description 24
- 244000130270 Fagopyrum tataricum Species 0.000 claims abstract description 23
- 235000014693 Fagopyrum tataricum Nutrition 0.000 claims abstract description 23
- 241000132446 Inula Species 0.000 claims abstract description 23
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 23
- 244000252132 Pleurotus eryngii Species 0.000 claims abstract description 22
- 235000001681 Pleurotus eryngii Nutrition 0.000 claims abstract description 22
- 235000003417 Plumeria rubra f acutifolia Nutrition 0.000 claims abstract description 22
- 244000040691 Plumeria rubra f. acutifolia Species 0.000 claims abstract description 22
- 241000304432 Sedum sarmentosum Species 0.000 claims abstract description 22
- 235000021307 Triticum Nutrition 0.000 claims abstract description 22
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 21
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 21
- 240000001851 Artemisia dracunculus Species 0.000 claims abstract description 21
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 21
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 21
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 21
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 21
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 21
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 21
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 18
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 18
- 229930003944 flavone Natural products 0.000 claims abstract description 18
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 18
- 235000011949 flavones Nutrition 0.000 claims abstract description 18
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 244000269722 Thea sinensis Species 0.000 claims abstract 9
- 241000209140 Triticum Species 0.000 claims description 21
- 241001247821 Ziziphus Species 0.000 claims description 16
- 239000002994 raw material Substances 0.000 claims description 13
- 238000007796 conventional method Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 46
- 230000000694 effects Effects 0.000 abstract description 38
- 229940079593 drug Drugs 0.000 abstract description 23
- 206010067125 Liver injury Diseases 0.000 abstract description 21
- 210000004369 blood Anatomy 0.000 abstract description 20
- 239000008280 blood Substances 0.000 abstract description 20
- 231100000753 hepatic injury Toxicity 0.000 abstract description 14
- 208000010706 fatty liver disease Diseases 0.000 abstract description 11
- 208000004930 Fatty Liver Diseases 0.000 abstract description 10
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 10
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 10
- 230000003908 liver function Effects 0.000 abstract description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 8
- 244000126002 Ziziphus vulgaris Species 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 6
- 235000006545 Ziziphus mauritiana Nutrition 0.000 abstract description 4
- 235000008529 Ziziphus vulgaris Nutrition 0.000 abstract description 4
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 4
- 150000002632 lipids Chemical class 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 235000012000 cholesterol Nutrition 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 244000098338 Triticum aestivum Species 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 32
- 239000013641 positive control Substances 0.000 description 31
- 210000002966 serum Anatomy 0.000 description 23
- 239000011550 stock solution Substances 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 13
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 12
- 239000013642 negative control Substances 0.000 description 11
- 229930003935 flavonoid Natural products 0.000 description 10
- 235000017173 flavonoids Nutrition 0.000 description 10
- 210000005228 liver tissue Anatomy 0.000 description 10
- 150000002215 flavonoids Chemical class 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 102100030797 Conserved oligomeric Golgi complex subunit 2 Human genes 0.000 description 6
- 101000920113 Homo sapiens Conserved oligomeric Golgi complex subunit 2 Proteins 0.000 description 6
- 231100000439 acute liver injury Toxicity 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 206010023126 Jaundice Diseases 0.000 description 5
- 210000000941 bile Anatomy 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
- 229960002855 simvastatin Drugs 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 150000003648 triterpenes Chemical class 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000202726 Bupleurum Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229960003194 meglumine Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 229940043175 silybin Drugs 0.000 description 2
- 235000014899 silybin Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241000092668 Artemisia capillaris Species 0.000 description 1
- 235000008658 Artemisia capillaris Nutrition 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- -1 coumarin, flavonoid Chemical class 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种具有保肝护肝功效的保健茶,涉及中药保健品技术领域。本发明所述保健茶选用赶黄草、苦荞芽、旋覆花总黄酮、杏鲍菇多糖、小麦苗、槐花、炙甘草、金银花、垂盆草、茵陈、栀子、大枣多种成分,应用中医辩证原理科学配伍而得,诸药合用药效增强,以达到保肝、护肝、降血脂、抗血脂的功效。本发明保健茶能够帮助清除体内脂类及胆固醇,防止脂肪在肝脏等处堆积,有效预防脂肪肝、肝硬化等多因素肝损伤的形成,显著改善肝损害者的肝功能指标,帮助人体恢复肝脏的正常功能。本发保健茶由多种中药成分组成,对人体安全无害,无药物副作用,可长期服用。
Description
技术领域
本发明涉及保健食品领域,具体涉及一种具有保肝护肝功效的保健茶。
背景技术
肝脏是高等动物的重要器官,其代谢非常活跃,被称为动物机体的“代谢中心”,并与机体的生命健康、生长发育关系密切。肝脏具有生成纤溶因子、解毒排泄、分泌胆汁、免疫、凝血、生物代谢与转化等广泛的生理功能。然而肝脏是最敏感、脆弱的器官。睡眠不足、肥胖、血糖过高、过度饮酒、吸烟、熬夜、滥用药物、油腻食品等不良生活习惯都会加重肝脏的负担,对肝脏造成损害,进而发展成慢性肝炎、酒精性脂肪肝、非酒精性脂肪肝、慢性肝损伤等肝脏疾病,更甚至发展为肝癌。肝脏代谢功能一旦出现障碍,往往波及其他脏器,容易导致机体免疫功能低下、物质转化功能障碍、凝血不良以及胆汁分泌和排泄障碍等病症,继而引发全身性器官功能不全,严重影响生长发育和健康。因此保护肝脏对防治疾病以及保障机体健康具有重要意义。
当前市场上护肝保肝的产品种类繁多,中药类护肝便是其中一种。护肝中药具有残留少、毒副作用轻微以及不易形成耐药性等优点;且中药具有来源广泛、药食同用的特点,其效果确切被大众所广泛认同。中药的多成分决定了护肝中药具有多靶点、多方位综合预防和治疗作用的特点,其中中药有效成分中的多糖类、苷类、甾醇类等对肝脏均有较好的保护作用。寻找具有保肝护肝功效的复方中药保健茶,加强日常保健,对预防肝病具有重要意义。
发明内容
(一)解决的技术问题
针对现有技术的不足,本发明提供了一种具有保肝护肝的保健茶。
(二)技术方案
为实现以上目的,本发明通过以下技术方案予以实现:
一方面,本发明提供了一种具有保肝护肝的保健茶,所述保健茶是由以下重量份数的原料组成:赶黄草10-30份、苦荞芽10-30份、旋覆花总黄酮5-20份、杏鲍菇多糖10-30份、小麦苗10-30份、槐花10-30份、炙甘草5-20份、金银花5-20份、垂盆草5-20份、茵陈5-20份、栀子1-10份、大枣5-15枚。
优选地,所述保健茶是由以下重量份数原料组成:赶黄草15-25份、苦荞芽15-25份、旋覆花总黄酮10-20份、杏鲍菇多糖15-25份、小麦苗15-25份、槐花15-25份、炙甘草5-15份、金银花5-15份、垂盆草10-20份、茵陈10-20份、栀子4-8份、大枣5-10枚。
优选地,所述保健茶是由以下重量份数原料组成:赶黄草20份、苦荞芽20份、旋覆花总黄酮10份、杏鲍菇多糖20份、小麦苗20份、槐花20份、炙甘草9份、金银花12份、垂盆草15份、茵陈12份、栀子6份、大枣6枚。
所述保健茶可以按照常规方法制备成各种内服制剂,包括但不限于颗粒剂、汤剂、袋泡茶等剂型。
本发明保健茶中各成分的药理作用:
赶黄草:味甘,性温,归肝、肾经;有利水除湿、祛瘀止痛功效;用于晃荡、水肿、跌打损伤、肿痛等病症;赶黄草中主要含有类黄酮类、木脂素类、香豆素类、苯乙酮类、鞣质类、三萜类等多种化学成分;现代药理研究表明赶黄草含有多种有效成分均对肝损伤具保护作用和修复作用,能恢复肝脏功能,减低饮酒及药物对肝脏的损害,抑制肝纤维化、肝硬化,并对甲肝、乙肝、慢性病毒性肝炎具有显著的治疗作用,还具有抗氧化、利胆等功效。。
苦荞芽:味苦、性平;有理气止痛、健脾利湿的功效;用于治疗胃痛、消化不良、腰腿疼痛、跌打损伤等症;苦荞芽中富含蛋白质、纤维素、维生素、矿物质、黄酮类物质和各种活性物质;现代医学研究表明,其具有降血糖、降血脂、降尿酸、防便秘、增强机体免疫力等作用。
旋覆花总黄酮:为旋覆花中主要的化学成分,具有抗氧化、降脂、抗炎、抗肿瘤、抗动脉硬化、镇痛等药理活性作用。
杏鲍菇多糖:有降血糖,增强机体免疫功能,抗病毒,抗肿瘤,降低机体胆固醇含量,降血脂,防治动脉硬化等药理作用。
小麦苗:味辛,性寒,归心、小肠经;具有清热解毒的功效,用于除烦热、疗黄疸、解酒毒等症。
槐花:味苦,性微寒,归肝、大肠经;有凉血止血、清肝泻火的功效;主治肠风便血、痔血、肝火头痛、目赤肿痛等病症;槐花含有芦丁、槲皮素、鞣质、槐花二醇、维生素A等物质,有降血压、扩张冠状动脉、抗氧化、抗菌、止血等药理作用。
炙甘草:味甘,性温,归心、肺、胃、脾经;具有补脾和胃,益气复脉、调理阴阳、气血双补等功效;用于治疗脾胃虚弱、倦怠乏力、心悸动、脉结代等病症;炙甘草中含有黄酮类、三萜类、多糖、生物碱等有效成分,现代医学研究表明炙甘草有抗抑郁、改善免疫功能、调节心律失常、抗肿瘤、抗炎等功效。
金银花:味甘,性寒,归肺,胃经;具有清热解毒、消炎退肿等功效;用于外感风热或温病发热,中暑,热毒血痢,痈肿疔疮,喉痹等多种感染性疾病治疗;金银花中主要含有黄酮类、有机酸类、挥发油类、环烯醚萜类等有效成分;现代药理学研究表明,金银花具有抗炎、抗氧化、抗紫外线损伤、降血脂、降血糖、抗病毒等作用。
垂盆草:味甘、淡,性微凉,归肝、胆、小肠经;具有清热解毒、利尿消肿、排脓生肌、降低谷丙转氨酶的作用;用于湿热黄疸、小便不利、痈肿疮疡及急慢性肝炎等症;其主要含有黄酮类、甾醇类、生物碱类、三萜类、氨基酸及挥发油等化学成分;具有保肝、抗炎、抗氧化、抗肿瘤、免疫调节及增强肌力等作用。
茵陈:味微苦微辛,性微寒,归脾、胃、膀胱经;有清利湿热、利胆退黄等功效,主治黄疸尿少、湿温署湿、闻疮瘙痒等症;其主要含有香豆素、黄酮类、有机酸类、挥发油类、萜类等化学成分;具有保肝利胆、抗炎、抗氧化、抗肿瘤、抑菌和抗病毒等药理作用。
栀子:味苦,性寒;归心、肺、三焦经;泻火除烦、清热利湿、凉血解毒;用于热病心烦、湿热黄疸、淋证涩痛、目赤肿痛等症。
大枣:味甘,性温,归脾、胃经;有补脾和胃,益气生津,调营卫,解药毒之功效;用于治胃虚食少,脾弱便溏,气血津液不足,营卫不和,心悸怔忡等病症;大枣中含有丰富的营养物质,包括氨基酸类、糖类、维生素和多种微量元素,且含有大量的核苷酸衍生物,大枣对肿瘤、高血压、高胆固醇血症等疾病具有较好的辅助治疗效果,具有延缓衰老、抗氧化、提高免疫、保护肝脏、等作用。
(三)有益效果
本发明提供了一种具有保肝护肝功效的保健茶。本发明所述保健茶选用赶黄草、苦荞芽、旋覆花总黄酮、杏鲍菇多糖、小麦苗、槐花、炙甘草、金银花、垂盆草、茵陈、栀子、大枣多种成分,应用中医辩证原理科学配伍而得,诸药合用药效增强,以达到保肝、护肝、降血脂、抗血脂的功效。本发明保健茶能够帮助清除体内脂类及胆固醇,防止脂肪在肝脏等处堆积,有效预防脂肪肝、肝硬化等多因素肝损伤的形成,显著改善肝损害者的肝功能指标,帮助人体恢复肝脏的正常功能。本发保健茶由多种中药成分组成,对人体安全无害,无药物副作用,可长期服用。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
一种具有保肝护肝的保健茶,所述保健茶是由以下重量份数的原料组成:赶黄草10份、苦荞芽10份、旋覆花总黄酮5份、杏鲍菇多糖10份、小麦苗10份、槐花10份、炙甘草5份、金银花5份、垂盆草5份、茵陈5份、栀子1份、大枣5枚。
实施例2
本实施例与实施例1的区别在于:所述保健茶是由以下重量份数的原料组成:赶黄草30份、苦荞芽30份、旋覆花总黄酮20份、杏鲍菇多糖30份、小麦苗30份、槐花30份、炙甘草20份、金银花20份、垂盆草20份、茵陈20份、栀子10份、大枣15枚。
实施例3
本实施例与实施例1的区别在于:所述保健茶是由以下重量份数的原料组成:赶黄草18份、苦荞芽26份、旋覆花总黄酮8份、杏鲍菇多糖20份、小麦苗26份、槐花18份、炙甘草12份、金银花16份、垂盆草8份、茵陈16份、栀子4份、大枣8枚。
实施例4
本实施例与实施例1的区别在于:所述保健茶是由以下重量份数原料组成:赶黄草15份、苦荞芽15份、旋覆花总黄酮10份、杏鲍菇多糖15份、小麦苗15份、槐花15份、炙甘草5份、金银花5份、垂盆草10份、茵陈10份、栀子4份、大枣5枚。
实施例5
本实施例与实施例1的区别在于:所述保健茶是由以下重量份数原料组成:赶黄草25份、苦荞芽25份、旋覆花总黄酮20份、杏鲍菇多糖25份、小麦苗25份、槐花25份、炙甘草15份、金银花15份、垂盆草20份、茵陈20份、栀子8份、大枣10枚。
实施例6
本实施例与实施例1的区别在于:所述保健茶是由以下重量份数原料组成:赶黄草18份、苦荞芽22份、旋覆花总黄酮15份、杏鲍菇多糖22份、小麦苗16份、槐花18份、炙甘草8份、金银花10份、垂盆草12份、茵陈16份、栀子5份、大枣5枚。
实施例7
本实施例与实施例1的区别在于:所述保健茶是由以下重量份数原料组成:赶黄草20份、苦荞芽20份、旋覆花总黄酮10份、杏鲍菇多糖20份、小麦苗20份、槐花20份、炙甘草9份、金银花12份、垂盆草15份、茵陈12份、栀子6份、大枣6枚。
试验例1
1材料与方法
1.1试验药品
配方1:赶黄草20份、苦荞芽20份、旋覆花总黄酮10份、杏鲍菇多糖20份、小麦苗20份、槐花20份、炙甘草9份、金银花12份、垂盆草15份、茵陈12份、栀子6份、大枣6枚。
配方2:赶黄草20份、苦荞芽20份、小麦苗20份、槐花20份、炙甘草9份、金银花12份、垂盆草15份、茵陈12份、栀子6份、大枣6枚。
配方3:赶黄草20份、旋覆花总黄酮10份、杏鲍菇多糖20份、小麦苗20份、槐花20份、炙甘草9份、金银花12份、垂盆草15份、茵陈12份。
配方4:赶黄草20份、苦荞芽20份、旋覆花总黄酮10份、杏鲍菇多糖20份、小麦苗20份、槐花20份、垂盆草15份、栀子6份、大枣6枚
配方5:赶黄草20份、苦荞芽20份、旋覆花总黄酮10份、杏鲍菇多糖20份、炙甘草9份、金银花12份、茵陈12份、栀子6份、大枣6枚。
配方6:苦荞芽20份、旋覆花总黄酮10份、杏鲍菇多糖20份、小麦苗20份、槐花20份、炙甘草9份、金银花12份、垂盆草15份、茵陈12份。
将上述中药原料洗净、烘干、粉碎后按照常规煎煮方法制备成中药原液,浓度为0.2mL/g(每毫升相当于原生药材0.2g),0-4℃冰箱保存,备用。
阳性对照药物1:柴胡疏肝散
阳性对照药物2:水飞蓟宾葡甲胺片
阳性对照药物3:辛伐他丁
1.2试验动物
SD大鼠,雄性,220只,(200±20)g,SPF级
1.3试验方法
1.3.1四氯化碳诱导大鼠急性肝损伤
SD大鼠,雄性,100只。按体重随机分为阴性对照组、模型组、试验1-6组、阳性对照1组、阳性对照2组。阴性对照组、模型组每天给予等量的纯净水,试验1-6组动物每天按照10mL/kg体质量分别灌胃配方1-6的原液;;阳性对照1组动物每天按照10mL/kg体质量分别灌胃浓度为0.5g/mL的阳性对照药物1;阳性对照2组动物灌胃阳性对照药物2(药物剂量为5mg/kg);各组动物给药1天1次,连续给药10天;各组动物于给药第4天、第8天,按体质量5mL/kg一次性皮下注射四氯化碳,制备急性大鼠肝损伤模型,其中阴性对照组大鼠不造模。造模后禁食不禁水,12h后,经乙醚麻醉后眼眶静脉丛采血,测定血清AST、ALT、SOD、MDA、GSH含量;取肝脏组织,检测肝组织SOD、MDA、GSH含量。
1.3.2高脂饲料诱导脂肪肝大鼠模型
SD大鼠,雄性,120只。按体质量用随机数字法随机分成2组,10只大鼠给予维持饲料作为阴性对照组,110只给予模型饲料作为模型组;喂养2周后,根据血清总胆固醇(TC)水平将模型组用随机数字法随机分为7组,即模型组(不给药)、阳性对照组(阳性对照药物3,给药剂量为3mg/kg)、试验1-6组(配方1-6的原液,各组动物每天按照10mL/kg体质量分别灌胃相应药物),每组10只,分组后,给药1天1次,连续给药30天。阴性对照组继续给予维持饲料,其余各组继续给予模型饲料。于试验结束时不禁食,乙醚麻醉后经眼内眦采血,测定血清TC、TG、LDL-C、HDL-C;采血处死后迅速剖腹取肝,生理盐水清洗并滤纸滤干血水,称肝脏重量并计算肝脏系数(每100g大鼠体重含肝脏g重)。
2结果与分析
2.1不同配方原液及阳性对照药物对四氯化碳诱导大鼠急性肝损伤的影响
从表1可知,与阴性对照组相比,模型组血清ATS、ALT含量增加显著(P<0.01),表明大鼠急性肝损伤模型建模成功;与模型组相比,试验1-6组及阳性对照1-2组的血清ATS、ALT含量显著下降(P<0.01),血清SOD含量显著增加(P<0.01);与模型组相比,试验1-2组血清MDA含量显著下降(P<0.05),阳性对照1-2组血清MDA含量显著下降(P<0.01),试验3-6组血清MDA含量下降但差异不显著(P>0.05);与模型组相比,试验1-3组及阳性对照1-2组组血清GSH含量显著下降(P<0.01)。
从表2可知,在肝组织中,与阴性对照组相比,模型组肝组织的MDA含量显著增高(P<0.01),SOD、GSH含量显著降低(P<0.01);与模型组相比,试验1组和阳性对照2组肝组织的MDA含量显著降低(P<0.01),试验1组、阳性对照1-2组肝组织的SOD、GSH含量显著升高(P<0.01,P<0.05),其余各组的肝组织指标相比模型组略有升高或降低,差异不显著(P>0.05)。
表1不同配方原液及阳性对照药物对四氯化碳诱导大鼠急性肝损伤的血清指标影响
注:阴性对照组与模型组相比,*P<0.05,**P<0.01;模型组与各给药组相比▲P<0.05,▲▲P<0.01,下同。
表2不同配方原液及阳性对照药物对四氯化碳诱导大鼠急性肝损伤的肝组织指标影响
组别 | MDA/nmol·mL-1 | SOD/U·mL-1 | GSH/mg·L-1 |
阴性对照组 | 1.11±0.06** | 143.33±5.13** | 2.95±0.27** |
模型组 | 1.43±0.07 | 106.67±4.73 | 2.31±0.12 |
试验1组 | 1.23±0.11▲▲ | 142.33±8.39▲▲ | 2.76±0.09▲ |
试验2组 | 1.38±0.01 | 124.67±5.03 | 2.67±0.09 |
试验3组 | 1.38±0.02 | 123.00±3.00 | 2.58±0.03 |
试验4组 | 1.40±0.01 | 119.66±10.41 | 2.53±0.10 |
试验5组 | 1.39±0.03 | 119.34±2.52 | 2.57±0.05 |
试验6组 | 1.41±0.02 | 110.67±8.50 | 2.47±0.10 |
阳性对照1组 | 1.25±0.06▲▲ | 141.27±8.50▲▲ | 2.74±0.23▲ |
阳性对照2组 | 1.18±0.05▲▲ | 140.45±8.38▲▲ | 2.81±0.20▲ |
2.2不同配方原液及阳性对照药物对高脂饲料诱导大鼠脂肪肝的影响
由表3可知,造模两周后,与阴性对照组相比,各组血清TC、TG、LDLC含量均明显增加,血清HDLC显著下降(P<0.01),结果表明高脂饲料诱导的高血脂症大鼠建模成功。治疗30天后,与阴性对照组相比,模型组血清TC、TG、LDLC含量显著增加,血清HDLC显著下降(P<0.01);与模型组相比,阳性对照组及试验1-5组血清TC、TG含量显著降低(P<0.01),血清HDLC显著升高(P<0.01);与模型组相比,阳性对照组和试验1组血清LDLC含量显著降低(P<0.01),试验2-5组血清血清LDLC含量显著降低(P<0.05);与模型组相比,试验6-7组血清TC、TG、HDLC、LDLC含量略有降低或升高,差异不显著(P>0.05)。与模型组相比,各组肝脏系数均有降低,其中阳性对照组和试验1组显著降低(P<0.05)。
表3不同配方原液及阳性对照药物对高脂饲料诱导大鼠脂肪肝大鼠模型的影响
表4不同配方原液及阳性对照药物对高脂饲料诱导大鼠脂肪肝大鼠模型的影响
3结论
配方1-6的原液及阳性对照药物(柴胡疏肝散、水飞蓟宾葡甲胺片)均可以降低四氯化碳诱导急性肝损伤大鼠模型的血清中或肝脏组织中ATS、ALT、MDA、GSH的含量,增加血清或肝脏组织中SOD的含量增加,以上表明上述各药物具有一定的护肝作用。其中本发明保健茶的中药配方原液(即配方1)其降低或增加上述指标的效果与阳性对照药物相当,且明显优于其余各组配方的中药原液。试验6组(配方6)中的使用的原液缺少了赶黄草,其降低或增加上述指标的效果明显低于配方1-5的原液。
配方1-6的原液及阳性对照药物(辛伐他丁)均可降低高脂饲料诱导脂肪肝大鼠血清TC、TG、LDLC含量,提高血清HDLC含量,降低肝脏系数,以上表明上述各药物具有一定的护肝作用降血脂和抗脂肪肝作用。其中本发明保健茶的中药配方原液(即配方1)其降低或增加上述指标的效果与阳性对照药物相当,且明显优于其余各组配方的中药原液。试验6组(配方6)中的使用的原液缺少了赶黄草,其降低或增加上述指标的效果明显低于配方1-5的原液。
本发明所述保健茶选用赶黄草、苦荞芽、旋覆花总黄酮、杏鲍菇多糖、小麦苗、槐花、炙甘草、金银花、垂盆草、茵陈、栀子、大枣多种成分,应用中医辩证配伍而得,充分发挥各药作用,诸药共同协调增益药效,其中赶黄草在本发明保健茶中对保肝护肝作用的实现起到重要作用,本发明所述保健茶配方中各成分缺一不可,共同实现护肝、降血脂、改善脂肪肝的作用。
试验例2
实验人群:实验分为的40-50岁组、50-60岁组,每组选取生活习惯及生活水平相似的脂肪肝、酒精肝等肝损伤患者各30人。
实验方法:在实验开始之前通给各实验组人群进行一次肝功能检查,并记录检查结果。试验期间给实验人群服用本品,每日保健茶1份,30天后再次给试验人群进行一次肝功能检查,并与实验开始之前的结果比较,记录肝损伤的改善情况。试验期间,各组试验者需保持健康饮食及作息。
实验结果:
较好改善:肝损伤有明显改善,肝功能指标显著降低;
一般改善:肝损伤有轻微改善,肝功能指标有降低;
无改善:肝损伤情况无任何改善,肝功能指标无降低或增加。
表5人群观察实验结果
以上结果表明,连续服用本发明保健茶后,能够显著改善肝损害患者的肝功能指标,能够修复肝损伤,帮助患者恢复肝功能,对肝损伤患者的改善率能达到90%。
以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。
Claims (4)
1.一种具有保肝护肝的保健茶,其特征在于,所述保健茶是由以下重量份数的原料组成:赶黄草10-30份、苦荞芽10-30份、旋覆花总黄酮5-20份、杏鲍菇多糖10-30份、小麦苗10-30份、槐花10-30份、炙甘草5-20份、金银花5-20份、垂盆草5-20份、茵陈5-20份、栀子1-10份、大枣5-15枚。
2.根据权利要求1所述的一种具有保肝护肝的保健茶,其特征在于,所述保健茶是由以下重量份数原料组成:赶黄草15-25份、苦荞芽15-25份、旋覆花总黄酮10-20份、杏鲍菇多糖15-25份、小麦苗15-25份、槐花15-25份、炙甘草5-15份、金银花5-15份、垂盆草10-20份、茵陈10-20份、栀子4-8份、大枣5-10枚。
3.根据权利要求1所述的一种具有保肝护肝的保健茶,其特征在于,保健茶是由以下重量份数原料组成:赶黄草20份、苦荞芽20份、旋覆花总黄酮10份、杏鲍菇多糖20份、小麦苗20份、槐花20份、炙甘草9份、金银花12份、垂盆草15份、茵陈12份、栀子6份、大枣6枚。
4.如权利要求1至权利要求3任一项所述的一种具有保肝护肝的保健茶,其特征在于,所述保健茶按照常规方法制备成各种内服制剂,包括但不限于颗粒剂、汤剂、袋泡茶等剂型。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311495544.5A CN117562155A (zh) | 2023-11-10 | 2023-11-10 | 一种具有保肝护肝功效的保健茶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311495544.5A CN117562155A (zh) | 2023-11-10 | 2023-11-10 | 一种具有保肝护肝功效的保健茶 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117562155A true CN117562155A (zh) | 2024-02-20 |
Family
ID=89859874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311495544.5A Pending CN117562155A (zh) | 2023-11-10 | 2023-11-10 | 一种具有保肝护肝功效的保健茶 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117562155A (zh) |
-
2023
- 2023-11-10 CN CN202311495544.5A patent/CN117562155A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101090284B1 (ko) | 홍삼과 녹용 추출물을 포함하는 드링크제 및 그의 제조방법 | |
KR101787432B1 (ko) | 녹용 발효물과 효모 가수분해물을 함유한 생리불순 및 생리통 개선 한약 조성물 제조 방법 | |
CN102772781A (zh) | 一种治疗慢性结肠炎的中药制剂及其制备方法 | |
CN113499393A (zh) | 一种具有胃黏膜损伤保护作用的组合物及其制备方法 | |
KR101826737B1 (ko) | 생약재 추출물을 유효성분으로 하는 근육틱 및 우울증 개선용 조성물 및 그의 제조방법 | |
CN105288041A (zh) | 一种防治肾病综合征的中药制剂及制法 | |
EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
CN101254263A (zh) | 复方瓜子金口服液及其制备方法 | |
CN101085962A (zh) | 淡竹白茅酒 | |
KR101910013B1 (ko) | 한약재 추출물(socg)을 함유하는 통증의 개선, 예방 또는 치료용 조성물 | |
US20030143289A1 (en) | Herbal composition PHY828 and its use | |
CN107712890A (zh) | 一种宁心安神膏滋及其制备方法 | |
CN104398969A (zh) | 一种肾移植术后治疗保健中药 | |
KR100850503B1 (ko) | 복합 생약 추출물을 유효성분으로 함유하는 성기능 개선용조성물 | |
CN117562155A (zh) | 一种具有保肝护肝功效的保健茶 | |
KR20140108104A (ko) | 한인진 및 울금의 복합추출물을 유효성분으로 포함하는 비만 관련 질환의 예방, 억제 또는 치료용 조성물 | |
KR100712659B1 (ko) | 당뇨병 및 이로 인한 합병증 치료 및 예방용 한약조성물 | |
CN103007145B (zh) | 一种治疗小儿轮状病毒肠炎的中药组合物及其制备方法 | |
KR101093006B1 (ko) | 미생물을 이용한 우황 청심원 원료 함유 건강식품의 제조방법 및 그 제조방법에 의해 제조된 건강식품 | |
CN111084878A (zh) | 一种用于肺及呼吸系统疾病的生物医药、医用全营养食品及制备方法 | |
US6444236B1 (en) | Compositon containing medicinal herbs and young antlers of cornu cervi | |
CN109771567A (zh) | 一种中草药扶正化瘀排毒化肿瘤的配方 | |
KR101600745B1 (ko) | 생약 추출물을 포함하는 신경안정용 약학적 조성물 | |
CN108324783A (zh) | 白归参灵冬甘治癌药 | |
CN113101331B (zh) | 一种百里香药茶及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |